ONE NUCLEUS STRENGTHENS BOARD WITH APPOINTMENT OF NEW DIRECTOR

Life Sciences industry leader joins the region’s Life Science & Healthcare membership organisation
Cambridge, UK: 10 April 2024

Life Sciences industry leader joins the region’s Life Science & Healthcare membership organisation
Cambridge, UK: 10 April 2024
Dr Raza Ali and Prof James Brenton wish to recruit a student to work on the project entitled: Systems pathology of the breast tumour microenvironment in obesity.
This is a unique opportunity for PhD study in the world-leading Cancer Research UK Cambridge Institute (CRUK CI), to start a research career in an environment committed to training outstanding cancer research scientists of the future.
Detachin™ Cell Detachment Solution from Amsbio provides a superior alternative to Trypsin/EDTA for gentle detachment of adherent cells from in vitro growth vessels.
Highly accomplished senior real estate executive leader and investment professional, Andy Creighton, joins Howard Group
The UK is set to give a unique second life to used nuclear materials. A £9.9m investment from the Innovate UK Sustainable Medicines Manufacturing Innovation Programme (SMMIP), backed by a further £8.9m from industry, will support a major project to develop cutting-edge new treatments for cancer.
Led by United Kingdom National Nuclear Laboratory (UKNNL) and Medicines Discovery Catapult (MDC), the project will use a radionuclide called lead-212 to create treatments called Targeted Alpha Therapies.
Venture Partner at Samsara BioCapital, and former CSO and COO of Karus Therapeutics, brings deep scientific and industry experience to Mosaic’s Executive Leadership team
· Stephen will lead the Company’s scientific strategy, preclinical pipeline build and R&D organisation
Mursla Bio’s AI Precision Medicine Platform to inform drug development and patient stratification in metabolic liver disease
Cambridge, UK, and Boston MA, USA, 13 November 2025: Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to advance precision diagnostics and significantly improve chronic disease outcomes for at-risk patients, today announced a collaboration with a leading global pharmaceutical company recognized for its expertise in precision medicine and biomarker-guided drug development.
The United Kingdom Health Security Agency (UKHSA) is a system leader for health security; taking action internationally to strengthen global health security, providing trusted advice to government and the public and reducing inequalities in the way different communities experience and are impacted by infectious disease, environmental hazards, and other threats to health.
EDX Medical Ltd was founded by Professor Sir Chris Evans in early 2022 to provide a range of testing solutions from point of care to laboratory assays in a range of major diseases, including cancer, neurological disorders, cardio-metabolic and infectious diseases. Sir Chris was knighted for his services to the British biotechnology industry and is one of the UK’s leading entrepreneurs and investors, founding dozens of companies.
TTP is an employee-owned technology and product development consultancy, with a 40-year track record of partnering with ambitious clients to solve complex challenges and bring innovative, commercially successful solutions to market.
We invent, design, and manufacture impactful products and technologies across a wide range of industries – including healthcare, life science, energy, and communications – and at the intersection of engineering, physical science, and biology.